Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06461182 | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma(PentixaFor) | recruiting | Phase 2 | 15 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | completed | Phase 2 | 100 | Debiopharm International SAINDUSTRY | 9 | Jun 12, 2024 |
| clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 67 | Fudan UniversityOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL(DLBCL) | completed | Phase 2 | 3 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | terminated | Phase 2 | 3 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) | terminated | Phase 2 / Phase 3 | 277 | TG Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT03797456 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | completed | Phase 2 | 111 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00799513 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma(RV-NHL-PI351) | completed | Phase 2 | 48 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies(PLATFORM) | completed | Phase 1 / Phase 2 | 62 | CelgeneINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | terminated | Phase 2 | 5 | Epizyme, Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04508647 | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | completed | Phase 2 | 4 | University of Colorado, DenverOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | terminated | Phase 2 | 190 | Swiss Cancer InstituteOTHER | 6 | Mar 13, 2024 | clinicaltrials |
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05387616 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden(Alternative-C) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06290817 | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI | unknown | Phase 2 | 62 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | terminated | Phase 1 / Phase 2 | 9 | BioNova Pharmaceuticals (Shanghai) LTD.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL(HO152) | active not recruiting | Phase 2 | 97 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Feb 14, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05214183 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma(ALTAMIRA) | active not recruiting | Phase 2 | 81 | Nordic Lymphoma GroupNETWORK | 5 | Feb 12, 2024 | clinicaltrials |
| NCT05875428 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 136 | ADC Therapeutics S.A.INDUSTRY | 6 | Feb 6, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03399513 | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma(R-CHOEP-brut) | completed | Phase 2 | 40 | University Hospital MuensterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT01393756 | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma(R2-CHOP2) | completed | Phase 2 | 80 | The Lymphoma Academic Research OrganisationOTHER | 1 | Dec 5, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jun 14, 2024source: clinicaltrials